Novo Nordisk A/S $NVO Shares Bought by Bleakley Financial Group LLC

Bleakley Financial Group LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 20.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,618 shares of the company’s stock after buying an additional 13,075 shares during the quarter. Bleakley Financial Group LLC’s holdings in Novo Nordisk A/S were worth $2,779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Quotient Wealth Partners LLC grew its holdings in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after buying an additional 177 shares during the last quarter. Certuity LLC lifted its holdings in shares of Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after buying an additional 177 shares during the period. Oakworth Capital Inc. boosted its position in Novo Nordisk A/S by 41.6% in the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after purchasing an additional 182 shares in the last quarter. True North Advisors LLC boosted its holdings in Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after buying an additional 199 shares in the last quarter. Finally, Asio Capital LLC boosted its stake in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $50.56 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $71.79. The stock has a market capitalization of $225.77 billion, a PE ratio of 11.87, a PEG ratio of 4.48 and a beta of 0.77. The stock has a 50-day simple moving average of $45.89 and a 200-day simple moving average of $45.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on NVO. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. Wolfe Research assumed coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Finally, Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk won EU approval for its once-daily Wegovy pill, making it the first oral GLP-1 weight-loss treatment cleared across the European Union and expanding its obesity market reach. Novo Nordisk wins EU approval for Wegovy weight-loss pill
• Positive Sentiment: Novo Nordisk updated investors on a large Phase 3 heart failure-obesity study, suggesting continued pipeline progress in cardiometabolic disease, a major long-term growth area. Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial
• Positive Sentiment: Fresh hemophilia trial results for Mim8/concizumab showed sustained efficacy and safety, expanding evidence for Novo’s rare blood disorder portfolio. Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
• Positive Sentiment: Novo Nordisk said most patients are choosing its obesity pill over Eli Lilly’s newer entrant, reinforcing confidence in its competitive position in the weight-loss drug market. It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.
• Neutral Sentiment: Novo Nordisk also signed an agreement to evaluate a semaglutide implant, an early-stage move that adds optionality but is too preliminary to affect near-term results. Novo Nordisk signs pact to assess semaglutide implant
• Negative Sentiment: Sun Pharma won South Africa approval to launch a generic version of semaglutide, highlighting rising competitive pressure on Novo’s diabetes and obesity blockbusters. India’s Sun Pharma wins South Africa approval to launch generic Ozempic
• Negative Sentiment: Zacks Research downgraded Novo Nordisk to “strong sell,” which could weigh on sentiment despite the company’s positive operating news. Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.